SEHK:1801Biotechs
Innovent Biologics (SEHK:1801): Reconciling a 116x P/E With DCF-Suggested Upside
Innovent Biologics (SEHK:1801) has been on traders’ radar after a choppy stretch that includes a slight pullback today but a strong rebound over the past year. This has raised questions about what the market is really pricing in.
See our latest analysis for Innovent Biologics.
Despite the recent 1 week share price return of minus 10.07 percent and a 90 day share price return of minus 15.26 percent, Innovent’s 1 year total shareholder return of 121.23 percent signals that momentum is still...